NZ582045A - A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates - Google Patents

A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates

Info

Publication number
NZ582045A
NZ582045A NZ582045A NZ58204507A NZ582045A NZ 582045 A NZ582045 A NZ 582045A NZ 582045 A NZ582045 A NZ 582045A NZ 58204507 A NZ58204507 A NZ 58204507A NZ 582045 A NZ582045 A NZ 582045A
Authority
NZ
New Zealand
Prior art keywords
leu
gly
ala
pro
thr
Prior art date
Application number
NZ582045A
Other languages
English (en)
Inventor
Stephen Nilsson
Original Assignee
Zymenex As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymenex As filed Critical Zymenex As
Publication of NZ582045A publication Critical patent/NZ582045A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ582045A 2006-04-04 2007-04-04 A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates NZ582045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05

Publications (1)

Publication Number Publication Date
NZ582045A true NZ582045A (en) 2011-07-29

Family

ID=38472949

Family Applications (7)

Application Number Title Priority Date Filing Date
NZ582045A NZ582045A (en) 2006-04-04 2007-04-04 A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
NZ568728A NZ568728A (en) 2006-04-04 2007-04-04 A process for concentration of a aryl sulfatase A
NZ571610A NZ571610A (en) 2006-04-04 2007-04-04 A process for concentration of alpha mannosidase
NZ588903A NZ588903A (en) 2006-04-04 2007-04-04 A process for concentration of galactosycerebrosidase or porphobuilinogen deaminase
NZ62312307A NZ623123A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ607595A NZ607595A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Family Applications After (6)

Application Number Title Priority Date Filing Date
NZ568728A NZ568728A (en) 2006-04-04 2007-04-04 A process for concentration of a aryl sulfatase A
NZ571610A NZ571610A (en) 2006-04-04 2007-04-04 A process for concentration of alpha mannosidase
NZ588903A NZ588903A (en) 2006-04-04 2007-04-04 A process for concentration of galactosycerebrosidase or porphobuilinogen deaminase
NZ62312307A NZ623123A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ597548A NZ597548A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
NZ607595A NZ607595A (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Country Status (20)

Country Link
US (6) US20090246187A1 (enExample)
EP (4) EP2100898B1 (enExample)
JP (6) JP2009532394A (enExample)
KR (3) KR20150103339A (enExample)
CN (1) CN105233276A (enExample)
AU (2) AU2007234195B2 (enExample)
BR (1) BRPI0709737A2 (enExample)
CA (3) CA2882501C (enExample)
DK (1) DK2628746T3 (enExample)
ES (3) ES2744499T3 (enExample)
HU (1) HUE042402T2 (enExample)
IL (4) IL194267A (enExample)
MX (1) MX2008012748A (enExample)
NO (3) NO347673B1 (enExample)
NZ (7) NZ582045A (enExample)
PL (3) PL2100898T3 (enExample)
PT (1) PT2628746T (enExample)
SI (1) SI2628746T1 (enExample)
WO (1) WO2007112757A2 (enExample)
ZA (2) ZA200805346B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
NZ582045A (en) * 2006-04-04 2011-07-29 Zymenex As A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates
WO2011103877A1 (en) * 2010-02-24 2011-09-01 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
EP3103469B1 (en) 2010-06-25 2020-12-09 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
KR102537084B1 (ko) * 2010-06-25 2023-05-26 샤이어 휴먼 지네틱 테라피즈 인크. 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
HUE056884T2 (hu) 2010-06-25 2022-03-28 Shire Human Genetic Therapies Eljárások és készítmények arilszulfatáz-A CNS-be történõ beadására
ES2625511T3 (es) 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US20150284698A1 (en) * 2012-11-13 2015-10-08 Ace Biosciences A/S PURIFICATION OF RECOMBINANT HUMAN GALACTOCEREBROSIDE B-GALACTOSIDASE (rhGALC)
MX2015007494A (es) * 2012-12-11 2015-12-15 Centogene Ag Metodo para diagnosticar leucodistrofia metacromatica.
CN104903442A (zh) 2013-01-09 2015-09-09 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
EA038573B1 (ru) 2014-03-24 2021-09-16 Биовератив Терапьютикс Инк. Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения
WO2019045149A1 (en) * 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
JP2002501032A (ja) 1998-01-27 2002-01-15 ヘム−バイオテック エイ／エス 急性間欠性ポルフィリン症（ａｉｐ）及び他のポルフィリン症の治療方法
ES2421736T3 (es) * 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
TR200100303T2 (tr) * 1998-06-09 2001-06-21 Statens Serum Institut Damardan uygulanacak immünoglobülinler üretmek için yöntem ve başka immünoglobülin ürünleri.
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
CA2378373C (en) 1999-07-27 2011-12-13 Hemebiotech A/S Production of rhpbgd and new therapeutic methods for treating patients with acute intermittent porphyria (aip) and other porphyric diseases
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2002317701A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
EP1402014A1 (en) * 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2003212912A1 (en) * 2002-02-04 2003-09-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
EP1740204B1 (en) 2004-04-01 2018-03-14 Chiesi Farmaceutici S.p.A. Medicinal use of alpha-mannosidase
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
NZ582045A (en) * 2006-04-04 2011-07-29 Zymenex As A pharmaceutical composition comprising at least 10mg/mL of alfa mannosidase and less that 5% total protein aggregates

Also Published As

Publication number Publication date
JP2016104000A (ja) 2016-06-09
PL2631242T3 (pl) 2023-03-20
US20090246187A1 (en) 2009-10-01
AU2007234195B2 (en) 2013-02-07
KR20140057678A (ko) 2014-05-13
KR20150103339A (ko) 2015-09-09
IL194267A (en) 2015-10-29
BRPI0709737A2 (pt) 2011-07-26
NO20082510L (no) 2008-10-31
US9713634B2 (en) 2017-07-25
ES2928096T3 (es) 2022-11-15
PT2628746T (pt) 2019-04-23
US20170202927A1 (en) 2017-07-20
NZ588903A (en) 2012-08-31
AU2007234195A1 (en) 2007-10-11
ZA200805346B (en) 2018-11-28
AU2008229659A1 (en) 2008-10-23
EP2628746B1 (en) 2019-01-09
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
JP2014051503A (ja) 2014-03-20
IL241654B (en) 2019-02-28
EP2628746A3 (en) 2014-03-19
IL235982A0 (en) 2015-01-29
CA2882501C (en) 2021-09-07
AU2008229659B2 (en) 2013-01-31
HUE042402T2 (hu) 2019-06-28
CA2882501A1 (en) 2007-10-11
NO346368B1 (no) 2022-06-27
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
IL211905A0 (en) 2011-05-31
US20160193304A1 (en) 2016-07-07
CA2644642C (en) 2016-01-26
JP2009273469A (ja) 2009-11-26
KR101504969B1 (ko) 2015-03-24
EP2631242B1 (en) 2022-08-03
EP2004672B1 (en) 2015-08-19
US20180289777A1 (en) 2018-10-11
EP2100898A1 (en) 2009-09-16
JP2013236633A (ja) 2013-11-28
EP2631242A3 (en) 2013-10-02
CA2632528C (en) 2022-07-12
NO347673B1 (no) 2024-02-19
NZ568728A (en) 2011-09-30
NZ607595A (en) 2014-10-31
ES2713488T3 (es) 2019-05-22
CN105233276A (zh) 2016-01-13
NO20084776L (no) 2008-10-31
NO20211305A1 (no) 2008-10-31
EP2631242A2 (en) 2013-08-28
EP2628746A2 (en) 2013-08-21
JP5384232B2 (ja) 2014-01-08
ES2744499T3 (es) 2020-02-25
SI2628746T1 (sl) 2019-04-30
NZ623123A (en) 2015-04-24
US20140314735A1 (en) 2014-10-23
US20120076767A1 (en) 2012-03-29
NZ597548A (en) 2013-08-30
EP2004672A2 (en) 2008-12-24
CA2632528A1 (en) 2007-10-11
EP2100898B1 (en) 2019-06-19
WO2007112757A2 (en) 2007-10-11
JP5878152B2 (ja) 2016-03-08
JP2014058521A (ja) 2014-04-03
PL2628746T3 (pl) 2019-07-31
JP2009532394A (ja) 2009-09-10
PL2100898T3 (pl) 2019-11-29
KR20090018894A (ko) 2009-02-24
CA2644642A1 (en) 2007-10-11
ZA200809540B (en) 2019-09-25
DK2628746T3 (en) 2019-04-01
IL194267A0 (en) 2011-08-01
IL241654A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
KR101504969B1 (ko) 폴리펩타이드의 농축 방법
DK2538968T3 (en) PROCEDURE FOR THE PREPARATION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALFA MANNOSIDASE
US20030220274A1 (en) GLP-1 gene delivery for the treatment of type 2 diabetes
KR101158673B1 (ko) 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101819803B1 (ko) 혈소판 표적화 치료
TW200944227A (en) In vivo temporal control of activatable matrix-degrading enzymes
CN101410408A (zh) 用于浓缩多肽的方法
KR101535791B1 (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
DK1740204T3 (en) MEDICAL USE OF ALFA MANNOSIDASE
AU2013202948B2 (en) A process for concentration of a polypeptide
KR20220111294A (ko) 키메라 옵신 gpcr 단백질
KR102230593B1 (ko) 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 혈액응고 인자 유전자 발현 증가용 조성물
CN112980819A (zh) 视网膜色素变性动物模型的构建方法及其应用
KR102510154B1 (ko) 비만유래 2형 당뇨 예방 및 치료를 위한 내장지방 대식세포 표적 비바이러스성 유전자／전달체 복합체
KR20160079868A (ko) 바이러스 벡터 제조
AU774603B2 (en) Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US20030199073A1 (en) Production of recombinant human lysosomal alpha-mannosidase
CN112831524A (zh) 人工改造的重组腺病毒载体、由其包装的病毒及其应用
TW202302858A (zh) 治療糖尿病之胰島素基因療法
CN114196712B (zh) 一种固定化酶法生产l-鸟氨酸的方法
CN115109790A (zh) 一种重组a-L-艾杜糖醛酸普酶及其制备方法
CN110423776B (zh) 表达重组凝血因子fix的载体及其构建方法和应用
PT1740204T (pt) Utilização médica de alfa-manosidase
KR101728600B1 (ko) 자일로비오스 생산을 위한 β-자일로시다아제 발현 시스템
KR20210035126A (ko) 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 APR 2017 BY DENNEMEYER SA

Effective date: 20140314

ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 1353701, NILSSON, STEFAN, C/O ZYMENEX A/S DK, AFFILIATE SWEDEN, DALENUM 13, SE-18170 LIDINGO, SE

Effective date: 20140411

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

ASS Change of ownership

Owner name: CHIESI FARMACEUTICI S.P.A., IT

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2019 BY ANAQUA SERVICES

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317